Cercar
24/02/2023
Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: Critical appraisal of real-world data
Moret, C, Acosta-Isaac, R, Mojal, S, Corrochano, M, Jimenez, B, Plaza, M, Souto, JC. Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: Critical appraisal of real-world data. PLoS One. 2023; 18(2)DOI:10.1371/journal.pone.0279297. PMID:36827286. IF:2.900(Q1/3D).
01/01/2023
Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning
Muñoz A.J., Souto J.C., Lecumberri R., Obispo B., Sanchez A., Aparicio J., Aguayo C., Gutierrez D., Palomo A.G., Fanjul V., del Rio-Bermudez C., Viñuela-Benéitez M.C., Hernández-Presa M.Á.. Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning. THROMBOSIS RESEARCH. 2023; 228DOI:10.1016/j.thromres.2023.06.015. PMID:37348318. IF:3.700(Q1/3D).
01/08/2022
Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products
Megias-Vericat, JE, Boix, SB, Moreno, RB, Mingot-Castellano, ME, Lopez, MR, Hirnyk, MC, Arranz, JM, Villas, JMC, Guaita, SH, Meda, MM, Jaime, FL, Albo-Lopez, C, Palomero-Massanet, A, Seto, NV, Lecinena, IL, Haro, ARC, Andres, JLP. Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products. THROMBOSIS RESEARCH. 2022; 216DOI:10.1016/j.thromres.2022.06.001. PMID:35696967. IF:7.500(Q1/2D).
01/05/2022
Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH
Gonzalez-Porras, JR, Mateo, J, Gonzalez-Calle, V, Marco, P, Garcia-Gutierrez, V, Reverter, JC, Lecumberri, R. Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH. Clinical & Translational Oncology. 2022; 24(5)DOI:10.1007/s12094-021-02735-1. PMID:34850351. IF:3.400(Q3/6D).
01/05/2022
Superwarfarin poisoning: challenges still remain
Gil, AD, Suarez, GMG, Puig, CM, Ganoza, AH. Superwarfarin poisoning: challenges still remain. Bmj Case Reports. 2022; 15(5)DOI:10.1136/bcr-2021-248385. PMID:35584857. IF:(Q/D).
01/02/2022
Clinical Efficacy and Safety of Fanhdi(R), a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study
Jimenez-Yuste, V, Alvarez-Roman, MT, Bravo, AP, Galmes, BJ, Hernandez, MDN, Hidalgo, OB, Alonso, CM, Gonzalez, NFP, Coll, J, Nunez, R, Carrasco, M, Candel, FG, Gonzalez-Porras, JR, Garcia, CH, Castro, MJV, Mir, R. Clinical Efficacy and Safety of Fanhdi(R), a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS. 2022; 28DOI:10.1177/10760296221074348. PMID:35108125. IF:2.900(Q3/6D).